FDA chief counsel
This article was originally published in The Rose Sheet
Executive Summary
Daniel Troy, a partner at Wiley, Rein & Fielding (Washington, D.C.), is designated the agency's top attorney. Troy is known in health care circles as one of the attorneys who successfully challenged FDA's approach under the Clinton Administration to off-label drug and medical device promotions in the Washington Legal Foundation v. Henney suit. He will report to another ex-Wiley, Rein & Fielding partner, Alex Azar, who was confirmed as HHS general counsel Aug. 3
You may also be interested in...
Deputy Chief Counsel Masoudi Will Succeed Troy In Acting Capacity
Gerald Masoudi will be FDA's acting chief counsel after Daniel Troy departs Nov. 24
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program